|Bid||39.30 x 800|
|Ask||40.16 x 800|
|Day's Range||36.20 - 40.65|
|52 Week Range||34.56 - 46.39|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-2.57%|
|Beta (5Y Monthly)||1.51|
|Expense Ratio (net)||0.79%|
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. Likewise, traders can also use this list to spot potential trend reversal opportunities that may offer a generous risk/reward. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank 1 or 2 which are expected to outperform in the quarter ahead.